Programme Thesis
The EIC Accelerator funds deep-tech startups and SMEs developing breakthrough innovations with high risk and high potential to create new markets or disrupt existing ones, providing up to €2.5M in non-dilutive grant (plus equity option) to bridge the gap to commercial scale-up. It exists to de-risk transformative technologies that struggle to attract private investment alone, supporting them from TRL 5/6 through to market readiness.
Selection Criteria
- Eligibility: Single SME/start-up or individual intending to establish one; must be based in EU Member State or associated country (UK grant-only).
- Technology Readiness Level: TRL 5/6 or above envisaged; project must demonstrate a clear path to market.
- Innovation: Game-changing, science-based, breakthrough; must create new markets or disrupt existing ones.
- Risk: High technological, market, or regulatory risk that deters private investors.
- Team: Ambition, commitment, and capability to scale.
- Impact: Potential for European and global market creation, societal benefit, and job growth.
- Scalability: Clear business model and growth strategy.
- Evaluation stages: Step 1 (short proposal) – remote evaluation; Step 2 (full proposal) – expert panel; Step 3 (interview) – jury of investors and entrepreneurs.
Past Winners / Cohort Profiles
Past winners include deep-tech startups in biotech, AI, clean energy, and advanced materials. Archetypes: spin-outs from EU research institutes, early-stage companies with strong IP and validated prototypes, often with a scientific founder and a clear commercial plan. Named examples not on page, but typical winners have raised follow-on funding and demonstrate traction (e.g., clinical trials, pilot partnerships).
Ideal Candidate Fingerprint
A deep-tech startup with a breakthrough innovation at TRL 5-7, backed by strong scientific evidence and IP, targeting a large market with high societal impact. The team combines technical expertise with business acumen, has a clear scale-up plan, and can articulate how the innovation creates a new market or disrupts an existing one. The applicant should be an EU-registered SME or committed to relocating.
Recommended Framing
Eniola should position the venture as a breakthrough AI platform that solves a critical bottleneck in drug resistance prediction—enabling 100% mutation coverage without crystal structures, outperforming structure-limited tools by a wide margin. Emphasize the validated proof-of-concept (AUROC 0.804 on Platinum benchmark) and the clear path to market via partnerships with Servier and Paris-Saclay, framing the technology as a new market-creating tool for precision drug discovery and antimicrobial resistance. Highlight the founder's unique pharmacist-to-ML engineer background as a competitive advantage in understanding both the biological and computational sides.
Watch Out
Venture is not yet incorporated; EIC requires an SME or individual intending to set one up—incorporation must be completed before Step 2 full proposal. TRL is likely below 5/6 (proof-of-concept validated but not yet in real-world testing); need to demonstrate progress toward TRL 5/6 via pilot with Servier. Founder is sole author; EIC may view single-founder teams as higher risk—consider adding a co-founder or advisor with business/commercial experience. UK applicants are grant-only; if Eniola plans to base in France, this is fine, but relocation must be confirmed before full proposal.
Research History
2026-07-28 09:46 · high confidence